Get started
Author

H. Harold Li

Observed name: Haoran Li
ORCID: 0000-0002-8485-9378
Observed ORCID: 0000-0002-8485-9378
OpenAlex ID: A5079463343
The effect of integrating knowledge‐based planning with multicriteria optimization in treatment planning for prostate SBRT
2023 · Sandun Jayarathna, Xinglei Shen, et al. · Journal of Applied Clinical Medical Physics · 12
PDF
Enzalutamide in metastatic hormone-sensitive prostate cancer: results from the international, multicentre, real-world ARON-3 study
2026 · Thomas Büttner, Mimma Rizzo, et al. · Prostate Cancer and Prostatic Diseases · 8
PDF
Impact of enhanced leaf model on dose calculation accuracy in single‐isocenter multitarget stereotactic radiosurgery treatments
2025 · Hem Moktan, Hongyu Jiang, et al. · Journal of Applied Clinical Medical Physics · 8
PDF
Trends and Disparities in the Use of Next-Generation Sequencing in Patients With Cancer in the United States
2026 · Chadi Hage Chehade, Zeynep Irem Ozay, et al. · JAMA Network Open · 6
PDF
Doublet Versus Triplet Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer Patients with Bone Metastases: Results from the ARON-3 Study
2026 · Philipp Cornelius Mandel, Mike Wenzel, et al. · European Urology Oncology · 3
Treatment Patterns and Attrition in Metastatic Castration-Resistant Prostate Cancer
2026 · Gabriel Hooper, Yeonjung Jo, et al. · JAMA Network Open · 1
Evaluation of atezolizumab, durvalumab, lurbinectedin, and tarlatamab in high-grade extrapulmonary neuroendocrine carcinoma: A multicenter retrospective comparative analysis.
2026 · Ty Michael Moore, Courtney C. Cavalieri, et al. · Journal of Clinical Oncology · 1
PDF
Improving VMAT dose calculation accuracy and planning quality via a GPU‐accelerated Fourier transform dose calculation algorithm
2025 · Kenny Guida, Chaoqiong Ma, et al. · Journal of Applied Clinical Medical Physics · 1
PDF
Bone-Modifying Agents in Metastatic Castration-Resistant Prostate Cancer
2026 · Zeynep Irem Ozay, Yeonjung Jo, et al. · JAMA Network Open
Analysis of corticosteroid exposure on efficacy of tarlatamab in small cell lung cancer: A multicenter retrospective study.
2026 · Ty Michael Moore, Courtney C. Cavalieri, et al. · Journal of Clinical Oncology
A late-phase randomized open-label multi-cohort trial to evaluate immune-related adverse events with different standard-of-care dosing strategies of standard-of-care immunotherapies: ImmuRAd trial.
2026 · Anup Kasi, Anusha Chidharla, et al. · Journal of Clinical Oncology
Transient prostate-specific antigen flare induced by lutetium Lu 177 vipivotide tetraxetan in patients with metastatic castration resistant prostate cancer.
2026 · Tiewei Cheng, Kirstin Binz, et al. · Journal of Clinical Oncology
Real-World effectiveness of second-line cabozantinib in metastatic renal cell carcinoma in the era of immunotherapy combinations: Results from the international metastatic renal cell carcinoma database consortium (IMDC)
2026 · Martin Zarba, Dylan E. O’Sullivan, et al. · Kidney Cancer
ADC target signatures in urothelial carcinoma: A transcriptomic framework for precision therapy.
2026 · Edwin Lin, Feng Bing-Jian, et al. · Journal of Clinical Oncology
Real-world comparative effectiveness of first-line (1L) cabozantinib (C) versus cabozantinib with nivolumab (C+N) in patients (pts) with metastatic papillary renal cell carcinoma (mPRCC).
2026 · Micah Ostrowski, Yeonjung Jo, et al. · Journal of Clinical Oncology
A phase II open-label study of enfortumab vedotin in patients with previously treated locally advanced, recurrent, or metastatic pancreatic adenocarcinoma (EPIC).
2026 · Anup Kasi, Raed Moh'd Taiseer Al-Rajabi, et al. · Journal of Clinical Oncology
PDF
Delta-Like Ligand 3 Expression by Immunohistochemistry in Rare Neuroendocrine Neoplasms and Associated Response to Off-Label Tarlatamab Treatment
2026 · Timothy Schieber, Jacob Hobbs, et al. · JCO Precision Oncology
Works count: 17
Citation count: 38
H-index: 4
I10-index: 1
Year
Topic
Type